MDxHealth S.A. MDXH 深 滬
等待開盤 06-25 09:30:00 美东时间
0.4698
-0.045
-8.76%
華盛通- 最 高0.5456
- 今 開0.52
- 成交量 80.49万股
- 最 低 0.4698
- 昨 收 0.5149
- 總市值 2.41万
- 52周最高 5.33
- 市盈率 靜 --
- 換手率 1567.03%
- 52周最低 0.4698
- 委 比 92.40%
- 總股本 5.14万
- 歷史最高 131.70
- 量 比 1.03
- 振 幅 14.72%
- 歷史最低 0.4698
- 每 手 1
- 風險率 1.11%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 阿里、京东、英伟达、思科等获多家大行上调目标价；Doximity、Dynatrace、Enovix、Wix.com等遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Autolus Therapeutics"买入"评级，目标价从9美元升至10美元；Maxim Group：维持Rezolute"买入"评级，目标价从4美元升至10美元
05-15 10:49
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Alpha Compute (NASDAQ:ALP) shares increased by 71.3% to $0.46 during T...
05-14 20:05
BTIG Maintains Buy on MDxHealth, Lowers Price Target to $4
BTIG analyst Mark Massaro maintains MDxHealth (NASDAQ:MDXH) with a Buy and lowers the price target from $7 to $4.
05-14 18:07
电话会总结 ｜ MDxHealth(MDXH)2026财年Q1业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据MDxHealth业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** - 报告营收：2740万美元（包含已停止的Resolve UTI业务） - 前瞻性营收（核心前列腺癌业务）：2390万美元，同比增长11% **盈利能力：** - 前瞻性毛利润：1500万美元 - 前瞻性毛利率：62.9% - 前瞻性经营亏损：790万美元 - 前瞻性净亏损：940万美元 **现金状况：** - 季度末现金及现金等价物：4320万美元 - 扣除收购款项后调整现金：2820万美元（扣除向Exact Sciences支付的1500万美元收
05-14 12:01
美股夜盘 | Linkers Industries Limited Class A涨31.85%，IP Strategy Holdings, Inc.涨24.83%
MDxHealth S.A.涨-45.13%；沃氪医疗涨-26.81%；Motorsport Games, Inc. Class A涨-21.70%
05-14 08:05
MDxHealth Reports Q1 2026 Results: Full Earnings Call Transcript
On Wednesday, MDxHealth (NASDAQ:MDXH) discussed first-quarter financial results...
05-14 05:08
MDxHealth shares are trading lower after the company reported worse-than-expected Q1 financial results and cut its FY26 sales guidance below estimates.
MDxHealth shares are trading lower after the company reported worse-than-expect...
05-14 04:48
Earnings Scheduled For May 13, 2026
Companies Reporting Before The Bell • Similarweb (NYSE:SMWB) is estimated to re...
05-13 19:11
Mdxhealth Highlights Data from Oxford’s ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026
Mdxhealth presented findings from the GPS-ProMPT study at the 2026 EAU Congress, demonstrating that its Genomic Prostate Score (GPS mdx) test predicts adverse outcomes across various prostate cancer treatments. Led by Professor Freddie Hamdy of Oxford University, the study analyzed 409 patients over six years and found that GPS mdx accurately stratified treatment failure risks, supporting personalized care decisions. The test successfully identif...
03-16 20:00
Earnings Scheduled For February 26, 2026
Companies Reporting Before The Bell • Enovis (NYSE:ENOV) is estimated to report...
02-26 19:11
